6-hydroxymethyl-benzo[b]thiophene-2-carboxylic acid methyl ester | 850072-66-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 6-hydroxymethyl-benzo[b]thiophene-2-carboxylic acid methyl ester
• 英文别名: methyl 6-(hydroxymethyl)-1-benzothiophene-2-carboxylate
• CAS: 850072-66-1
• 化学式: C₁₁H₁₀O₃S
• 分子量: 222.265
• InChiKey: PYXKTZQIXBRGMF-UHFFFAOYSA-N

物化性质

• 沸点：
  393.0±27.0 °C(Predicted)
• 密度：
  1.349±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-hydroxymethyl-benzo[b]thiophene-2-carboxylic acid methyl ester 在 咪唑 、 lithium chloro-isopropyl-magnesium chloride 、 2,2,6,6-四甲基哌啶氧化物 、 lithium hydroxide monohydrate 、 碘苯二乙酸 、 magnesium 、 1,2-二溴乙烷 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.5h， 生成
  参考文献：
  名称：

  [EN] DIMERIC COMPOUNDS AS STING AGONISTS
  [FR] COMPOSÉS DIMÈRES UTILISÉS EN TANT QU'AGONISTES DE STING

  摘要：

  本公开涉及以下公式(I)、(II)、(III)、(IV)、(V)和(VI)的二聚体STING激动剂及其药用可接受盐。本公开还涉及制备这些化合物的方法以及使用这些化合物的方法。

  公开号：

  WO2021113679A1
• 作为产物：
  描述：

  4-醛基-3-硝基苯甲酸甲酯 在 吡啶 、 硼烷四氢呋喃络合物 、 potassium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 lithium iodide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 51.0h， 生成 6-hydroxymethyl-benzo[b]thiophene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  [EN] THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES
  [FR] DERIVES THIOPHENE ET BENZOTHIOPHENE D'ACIDE HYDROXAMIQUE

  摘要：

  公开号：

  WO2005034880A3

文献信息

• SULFONAMIDES AS TRPM8 MODULATORS
  申请人：Branum Shawn T.

  公开号：US20120190674A1

  公开（公告）日：2012-07-26

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R 1 , R 2 , R 3 , and R 4 are defined herein.

  揭示了用于治疗各种疾病、综合征、症状和疾病的化合物、组合物和方法，包括疼痛。这些化合物由以下的化学式I所代表：其中A、B、G、Y、R1、R2、R3和R4在此处被定义。
• Thiophene and Benzothiophene Hydroxamic Acid Derivatives
  申请人：Miller A. Thomas

  公开号：US20070213392A1

  公开（公告）日：2007-09-13

  The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit historic deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一种新型的羟胺酸衍生物，其具有苯并噻吩或噻吩骨架。这些羟胺酸化合物可用于治疗癌症。这些羟胺酸化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导末端分化，阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物对于治疗具有肿瘤细胞增殖特征的患者是有用的。本发明的化合物还适用于预防和治疗TRX介导的疾病，例如自身免疫性、过敏性和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，例如神经退行性疾病。本发明还提供了包含羟胺酸衍生物的药物组合物和这些药物组合物的安全剂量方案，其易于遵循，并且在体内产生治疗有效量的羟胺酸衍生物。
• Benzothiophene hydroxamic acid derivatives
  申请人：Hubbs Jed Lee

  公开号：US20090069391A1

  公开（公告）日：2009-03-12

  The present invention relates to a novel class of hydroxamic acid derivatives. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一种新型的羟基酰胺衍生物。这些羟基酰胺化合物可用于治疗癌症。这些羟基酰胺化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导末端分化、阻止肿瘤细胞生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。本发明的化合物还可用于预防和治疗TRX介导的疾病，如自身免疫、过敏和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，如神经退行性疾病。本发明还提供包含羟基酰胺衍生物的药物组合物以及这些药物组合物的安全剂量方案，这些方案易于遵循，并在体内产生治疗有效量的羟基酰胺衍生物。
• Benzothiophene derivatives
  申请人：Hubbs Jed Lee

  公开号：US20090082308A1

  公开（公告）日：2009-03-26

  The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一类新型的苯并噻吩酰胺衍生物。这些羟肟酸化合物可用于治疗癌症。苯并噻吩酰胺化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导终末分化，阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。该发明的化合物也可用于预防和治疗TRX介导的疾病，如自身免疫性、过敏性和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，如神经退行性疾病。本发明还提供了包含羟肟酸衍生物的药物组合物和这些药物组合物的安全剂量方案，易于遵循，并在体内产生治疗有效量的羟肟酸衍生物。
• 2-HETEROARYLCARBOXYLIC ACID AMIDES
  申请人：Hendrix Martin

  公开号：US20120202842A1

  公开（公告）日：2012-08-09

  The invention relates to novel 2-heteroarylcarboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.

  本发明涉及新型2-杂环芳基羧酰胺，其制备过程以及它们用于制备治疗和/或预防疾病的药物和改善感知、注意力、学习和/或记忆的用途。